VP16-213 as a single agent in advanced testicular tumors

This publication has 10 references indexed in Scilit:

• EPIPODOPHYLLIN DERIVATIVE (VP 16-213) IN TREATMENT OF SOLID TUMOURS
  The Lancet, 1977
• EPIPODOPHYLLIN DERIVATIVE (VP 16-213) IN MALIGNANT TERATOMAS AND CHORIOCARCINOMAS
  The Lancet, 1977
• Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells
  Biochemistry, 1976
• VP 16-213 in acute myelogenous leukaemia
  Postgraduate Medical Journal, 1976
• Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.
  BMJ, 1975
• A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213
  Cancer, 1975
• Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas
  Cancer, 1974
• Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia—Haematosarcoma and Solid Tumours
  BMJ, 1973
• Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors
  European Journal of Cancer (1965), 1973
• CHEMOTHERAPY FOR METASTATIC TERATOMAS OF THE TESTIS
  British Journal of Urology, 1972